Current Opinion in Allergy and Clinical Immunology最新文献

The allergenic potential of enolases: physiological and pathophysiological insights. 烯醇化酶的致敏潜能：生理学和病理生理学的见解。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-03-26 DOI: 10.1097/ACI.0000000000001068

Sandra Pfeiffer, Ines Swoboda

{"title":"The allergenic potential of enolases: physiological and pathophysiological insights.","authors":"Sandra Pfeiffer, Ines Swoboda","doi":"10.1097/ACI.0000000000001068","DOIUrl":"10.1097/ACI.0000000000001068","url":null,"abstract":"Purpose of review: This review gives an overview on the current knowledge of the physiological and pathophysiological features of enolases and how these features might contribute to the enzymes' allergenic properties. It summarizes the most recent literature on allergenic enolases and raises questions that need to be answered in the future to gain a better understanding of the role of enolases in allergic diseases.Recent findings: The recent identification of two novel allergenic enolases, from London plane tree and whiff, further supports the uniqueness of this allergen family: the occurrence of enolases in the three major kingdoms of life and the capability to induce allergic symptoms via inhalation, ingestion, and skin contact.Summary: The importance and uniqueness of enolases as allergenic molecules is widely accepted. However, studies linking the biochemical and physiological features of enolases with their potential to induce allergies are still needed. This would contribute to a better understanding about the role of enolases in the induction of allergic diseases, to improve specificity and sensitivity of allergy diagnosis and to further enable the development of patient-tailored prophylactic and therapeutic approaches.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"212-219"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143708991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Standardizing outcomes in food allergy research: aligning clinical trials with patient priorities. 标准化食物过敏研究的结果：使临床试验与患者的优先级保持一致。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-04-21 DOI: 10.1097/ACI.0000000000001074

Daniel Munblit, Christian Apfelbacher, Anastasia Demidova, Audrey DunnGalvin, Robert J Boyle

{"title":"Standardizing outcomes in food allergy research: aligning clinical trials with patient priorities.","authors":"Daniel Munblit, Christian Apfelbacher, Anastasia Demidova, Audrey DunnGalvin, Robert J Boyle","doi":"10.1097/ACI.0000000000001074","DOIUrl":"https://doi.org/10.1097/ACI.0000000000001074","url":null,"abstract":"Purpose of review: This review explores the clinical outcomes used in immunoglobulin E (IgE)-mediated food allergy (FA) intervention studies, emphasizing unmet need for patient-centred outcomes. Standardizing outcome measurement is critical as research into FA treatments, particularly food immunotherapy, expands. Here we discuss how outcomes should reflect the multidimensional impact of FA on people's lives.Recent findings: Current evidence reveals a discrepancy between clinical trial outcomes and those most valued by patients and carers. While trials often prioritize changes in reactivity thresholds or immunological markers, patients and carers emphasize need in reducing severe reactions, improving quality of life, and enhancing confidence in disease management. This disparity highlights importance of harmonization efforts to guide FA research.The Core Outcome Measures for Food Allergy (COMFA) initiative recently identified two core outcomes - 'allergic symptoms' and 'quality of life' - through an international consensus process involving patients, caregivers, clinicians, and researchers. Outcomes like 'desensitization' and 'remission/sustained unresponsiveness' were considered important but were not seen as the most critical.Summary: Developing and implementing a COS for FA intervention studies is essential to align research with patient priorities, ensuring meaningful improvements in routine clinical care. Standardized outcome measurement will generate robust evidence, inform clinical practice, and empower patients and caregivers in decision-making about FA management.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":"25 3","pages":"172-184"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12052057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144062645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Doxycycline: lights and shadows of a mysterious treatment for chronic rhinosinusitis. 强力霉素：慢性鼻炎神秘疗法的光与影。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-02-12 DOI: 10.1097/ACI.0000000000001065

Minh P Hoang, Kachorn Seresirikachorn, Kornkiat Snidvongs

{"title":"Doxycycline: lights and shadows of a mysterious treatment for chronic rhinosinusitis.","authors":"Minh P Hoang, Kachorn Seresirikachorn, Kornkiat Snidvongs","doi":"10.1097/ACI.0000000000001065","DOIUrl":"10.1097/ACI.0000000000001065","url":null,"abstract":"Purpose of review: Chronic rhinosinusitis (CRS) is a diverse condition, including different underlying pathophysiologies. Tailoring the treatment for CRS depends on the individual's specific endotype and phenotype rather than using a universal approach. The emergence of biologics in recent years has raised questions about the role of antibiotics, particularly doxycycline, in CRS management. Insights from existing research on the mechanisms and appropriate use of doxycycline therapy may guide physicians in selecting the right treatment target.Recent findings: CRS with nasal polyps (CRSwNP) is frequently associated with type 2 inflammation and characterized by tissue remodeling process that can result in recalcitrant condition. Doxycycline therapy (100 mg daily) improves CRSwNP by exerting antitissue remodeling effects through matrix metalloproteinase inhibition. Doxycycline seems to provide benefits when used alongside adequate medicine treatment.Summary: Current evidence on the use of doxycycline therapy is limited to a small number of high-quality studies. Further research is needed to explore the duration and factors of success of doxycycline in treating CRS. Like other antibiotics, doxycycline has limitations related to side effects and the potential for antibiotic resistance. Therefore, treatment decisions should be made with caution, especially when doxycycline is used in combination with other pharmacologic therapies.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"151-156"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nasal allergen provocation test: updated indications and diagnostic accuracy. 鼻过敏原激发试验：最新适应症和诊断准确性。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-03-06 DOI: 10.1097/ACI.0000000000001066

Dichapong Kanjanawasee, Apinat Wattanaphichet, Pongsakorn Tantilipikorn, Bannawat Tantikun

{"title":"Nasal allergen provocation test: updated indications and diagnostic accuracy.","authors":"Dichapong Kanjanawasee, Apinat Wattanaphichet, Pongsakorn Tantilipikorn, Bannawat Tantikun","doi":"10.1097/ACI.0000000000001066","DOIUrl":"10.1097/ACI.0000000000001066","url":null,"abstract":"Purpose of review: The Nasal Allergen Provocation Test (NAPT) is a valuable diagnostic tool for allergic rhinitis, particularly in cases where conventional tests, such as the skin prick test (SPT) and serum-specific IgE (sIgE), yield inconclusive results. By replicating real-life allergen exposure in a controlled setting, NAPT enables the assessment of allergen-specific nasal reactivity. This article aims to review the current knowledge of NAPT.Recent findings: Recent studies have reinforced NAPT as the gold standard for confirming nasal allergic responses. In the past, test protocols, allergen dosages, and outcome measurements varied widely. However, advancements in allergen standardization, the combination of objective and subjective measurements, and metered nasal allergen application have led to an improved and more reliable test method, with ongoing efforts to establish a universal protocol for clinical testing.Summary: This review summarizes current knowledge on NAPT, including its clinical applications, indications, methodology, and recent advancements. Additionally, we compare NAPT with SPT and sIgE in terms of diagnostic accuracy. The protocols, allergen types and doses, test methodologies, and outcome measures of these studies were analyzed and compared.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"157-168"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions. 编辑介绍。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-05-01 DOI: 10.1097/ACI.0000000000001070

引用次数: 0

Outcomes in eosinophilic esophagitis: current understanding and future directions. 嗜酸性粒细胞性食管炎的结局：目前的认识和未来的方向。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-04-08 DOI: 10.1097/ACI.0000000000001071

Sara Urbani, Giulio Dinardo, Maria Cristina Artesani, Alessandro Fiocchi

{"title":"Outcomes in eosinophilic esophagitis: current understanding and future directions.","authors":"Sara Urbani, Giulio Dinardo, Maria Cristina Artesani, Alessandro Fiocchi","doi":"10.1097/ACI.0000000000001071","DOIUrl":"10.1097/ACI.0000000000001071","url":null,"abstract":"Purpose of review: Eosinophilic esophagitis (EoE) is a chronic, immune-mediated disorder that demands lifelong management due to its potential to progress to fibrosis and esophageal strictures. This review synthesizes current strategies for evaluating EoE outcomes and highlights emerging approaches aimed at reconciling the often discordant relationship between clinical symptoms and histologic findings. An updated synthesis is crucial to guide evolving clinical practices.Recent findings: Recent literature emphasizes the multifaceted nature of EoE, revealing limitations in traditional outcome measures. Advances in patient-reported outcomes (PROs), histologic scoring systems, and endoscopic assessments have enriched our understanding of disease activity. Furthermore, the integration of functional assessments through modalities such as high-resolution manometry and EndoFLIP, along with digital data integration, has refined disease monitoring and provided nuanced insights into treatment responses and long-term progression. Additionally, emerging evidence suggests that integrating novel biomarkers may further refine disease stratification and outcomes.Summary: A multidimensional approach that combines clinical, histologic, endoscopic, and functional data is crucial for personalized management of EoE. These insights pave the way for improved therapeutic decision-making and highlight the need for standardized, comprehensive tools in both clinical practice and future research. These additional findings advocate for a shift towards precision medicine, emphasizing multidisciplinary and patient-centric approaches.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"205-211"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143802695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From one biologic to another: the rationale and evidence behind switching therapies in chronic rhinosinusitis. 从一种生物到另一种：慢性鼻窦炎转换治疗的基本原理和证据。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-02-27 DOI: 10.1097/ACI.0000000000001067

Baharudin Abdullah, Farah Dayana Zahedi, Pongsakorn Tantilipikorn

{"title":"From one biologic to another: the rationale and evidence behind switching therapies in chronic rhinosinusitis.","authors":"Baharudin Abdullah, Farah Dayana Zahedi, Pongsakorn Tantilipikorn","doi":"10.1097/ACI.0000000000001067","DOIUrl":"10.1097/ACI.0000000000001067","url":null,"abstract":"Purpose of review: Although biologics had been used to treat CRSwNP, not all patients respond favourably, necessitating the use of other biologics. As there are currently no guidelines available, the process and rationale for switching biologic therapy in the treatment of CRSwNP are examined in this review.Recent findings: Due to the heterogeneity of diseases, biologic therapies may efficiently control CRSwNP but give inadequate control for asthma, or vice versa . Changing an ineffective first-line biologic to a second-line treatment or others is generally referred to as switching. The most common reasons for switching biologics are poor symptom management or ineffectiveness, and undesirable adverse effects. The ineffectiveness was largely due to the use of omalizumab or mepolizumab, whereas the adverse effects were due to dupilumab.Summary: Switching biologics is a nuanced process influenced by a variety of patient-specific and clinical factors. Biologics that effectively treat upper and lower airway diseases are recommended for optimal control in CRSwNP patients with concurrent asthma. There was no difference in outcomes between switching biologics with and without a washout period. Switching between biologics in the same class is generally not recommended. Dupilumab serves as an effective treatment option for refractory cases particularly aspirin-exacerbated respiratory disease.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"144-150"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143514982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Local allergic rhinitis in Asia: rethinking the allergy landscape. 亚洲局部变应性鼻炎：重新思考过敏景观。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-04-01 DOI: 10.1097/ACI.0000000000001069

Aneeza W Hamizan, Salina Husain, Pongsakorn Tantilipikorn

{"title":"Local allergic rhinitis in Asia: rethinking the allergy landscape.","authors":"Aneeza W Hamizan, Salina Husain, Pongsakorn Tantilipikorn","doi":"10.1097/ACI.0000000000001069","DOIUrl":"10.1097/ACI.0000000000001069","url":null,"abstract":"Purpose of review: Local allergic rhinitis (LAR) is increasingly recognized as a distinct phenotype of chronic rhinitis, yet its prevalence and characteristics in Asia remain underexplored. Given the variability in reported LAR prevalence across regions, this review re-evaluates the allergy landscape in Asia, considering environmental and immunological factors, as well as study methodology that may contribute to differences from Western populations.Recent findings: There were more Asian studies which reported lower prevalence (0-20%), in contrast to higher rates in Europe, particularly Mediterranean countries. Urbanization, air pollution, and high dust mite exposure may be important factors of nonatopic rhinitis in Asia. Diagnostic approaches, including nasal-specific IgE and provocation tests, vary across studies, impacting prevalence estimates.Summary: The lower reported LAR prevalence in Asia suggests potential differences in underlying mechanisms or diagnostic limitations. Further research is needed to refine diagnostic criteria, explore environmental triggers, and assess the clinical relevance of LAR in Asian populations. A better understanding of LAR in Asia could guide targeted management strategies and improve recognition of this condition in clinical practice.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":" ","pages":"135-143"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143751558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Common data elements for food allergy clinical trials: an overview. 食物过敏临床试验的常见数据要素：综述。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-04-21 DOI: 10.1097/ACI.0000000000001075

Shruti Sehgal, Justin Starren, Kyle Cattin, Lucy Bilaver, Anupama Gururaj, Alkis Togias, Ruchi S Gupta

{"title":"Common data elements for food allergy clinical trials: an overview.","authors":"Shruti Sehgal, Justin Starren, Kyle Cattin, Lucy Bilaver, Anupama Gururaj, Alkis Togias, Ruchi S Gupta","doi":"10.1097/ACI.0000000000001075","DOIUrl":"https://doi.org/10.1097/ACI.0000000000001075","url":null,"abstract":"Purpose of review: Food allergy represents a major public health issue, affecting about 8% of children and 11% of adults in the United States. Research in the field has rapidly expanded but is limited by a lack of standardized data fields or common data elements (CDEs) to record food allergy data. The present review focuses on the need for developing CDEs for food allergy, and their anticipated impact, as well as describes the central tenets of CDEs.Recent findings: Standardization of data definitions and consistency in data collection within a study and across multiple studies is a fundamental principle of clinical research. Several NIH centers have been collaborating to support the development of CDEs, thereby promoting the FAIR principles for clinical research.Summary: The population health burden of food allergies continues to rise in the absence of a standardized language for documenting food allergy clinical research data. Development and implementation of food allergy CDEs is needed both nationally and globally, to better understand and reduce the burden of this immune-mediated disease. When adopted, these CDEs will not only improve data consistency and interoperability but also speed up and improve the quality of future food allergy clinical trials.","PeriodicalId":10956,"journal":{"name":"Current Opinion in Allergy and Clinical Immunology","volume":"25 3","pages":"194-198"},"PeriodicalIF":3.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12043398/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Breaking down the tower of babel: common languages in food allergy studies. 打破巴别塔：食物过敏研究中的常用语言。

IF 3 4区医学

Current Opinion in Allergy and Clinical Immunology Pub Date : 2025-06-01 Epub Date: 2025-05-01 DOI: 10.1097/ACI.0000000000001073

Alessandro Fiocchi, Motohiro Ebisawa

引用次数: 0